---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-098380"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:31:11.837820+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# INmune Bio completes randomization of 208 patients in Phase 2 Alzheimer's trial; top-line data Q2 2025

## Summary
- Total of 208 patients enrolled, exceeding target; 56% mild AD and 44% MCI.
- Top-line cognitive results expected in Q2 2025 for the Phase 2 AD02 trial.
- Trial uses XPro to target glial-driven neuroinflammation in early Alzheimer's.
- Global, blinded, randomized Phase 2 trial; first doses administered to all patients.
- CEO RJ Tesi cited overenrollment as a major accomplishment for the company.

## SEC filing metadata
- accession: 0001213900-24-098380
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390024098380/0001213900-24-098380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390024098380/ea0221033-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-098380
- JSON: https://secwatch.observer/filing/0001213900-24-098380.json
- Plain text: https://secwatch.observer/filing/0001213900-24-098380.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.